Zextras Introduces Carbonio - A Private Digital Workplace
Zextras, the leading email and collaboration solutions provider, introduced Carbonio - a private digital workplace for the public sector and regulated industries.
Carbonio emerges as an exceptional solution for the public sector, enabling them to implement an extensive digital workspace for their internal teams and stakeholders. Delivering a suite of features that are not only comprehensive but also fully customizable, from emails and calendars to video meetings and file storage, Carbonio allows for superior adaptation to any unique technical requirements or business objectives. It is equally enticing for regulated industries to enhance their operations by providing secure software solutions tailored to meet the distinct security needs of their country and respective states.
The platform is rooted in robust compliance with global data protection regulations, including the European General Data Protection Regulation (GDPR). This fosters a secure digital environment for users, ensuring their data is aptly guarded. This high-powered alignment with stringent regulations further positions Carbonio as a reliable choice for businesses aiming to future-proof their operations while adhering to international privacy standards.
Carbonio is a complete and private alternative to Microsoft 365. It offers all the features of Microsoft 365 but with the added security and privacy required by the public sector and regulated industries. Carbonio can be hosted either in the customer's own data center, ensuring that all data remains under the customer's control, or by a local Cloud Service Provider (CSP) or Managed Service Provider (MSP), offering a Software as a Service (SaaS) solution that is fully compliant with local regulations.
"The public sector and regulated industries have been underserved in terms of privacy by the major providers of cloud-based productivity solutions," said Zextras CEO Paolo Storti. "Carbonio fills this gap by offering a complete and private alternative to Microsoft 365. We are excited to offer this solution to our customers."
Carbonio is available now. For more information, please visit https://www.zextras.com/carbonio
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129823111/en/
Contact information
Alberto Pittoni
Sales Director
+39 340 548 6681
Zextras
www.zextras.com
Sales@zextras.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
FPT and DENSO Sign MOU to Accelerate Software-Defined Vehicle Innovation13.12.2024 06:58:00 CET | Press Release
Global IT corporation FPT and global automotive components manufacturer DENSO signed a Memorandum of Understanding (MOU) to collaborate on advancing software-defined vehicles (SDV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212915049/en/ The signing ceremony took place at DENSO Corporation Aichi Headquarters with the participation of Dr Truong Gia Binh, Chairman of FPT Corporation, Mr Shinnosuke Hayashi, President & CEO of DENSO Corporation, and senior leaders of both companies. (Photo: Business Wire) Under this MOU, the two companies will develop software for next-generation SDVs, with a particular emphasis on mass-production projects for Advanced Driver Assistance Systems (ADAS). Both companies aim to build a high-speed, high-quality global development framework, with plans for expansion by the end of 2027. The partnership is backed by FPT’s two decades of experience in automotive, a global team of 5,000 automotive
Kao Corporation: Regarding Shareholder Statement13.12.2024 05:48:00 CET | Press Release
Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders. Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges. Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates. The timing of the announcem
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor13.12.2024 01:30:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally de
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas12.12.2024 23:30:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue1 of $10B - $20B. Data from t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom